17mg tirzepatide / Niacinamide Injection Tirzepatide | Pipeline Medical

MASH Therapy in 2026: Semaglutide vs Resmetirom Semaglutide leads in MASH resolution, weight loss, and metabolic improvement, while Resmetirom offers a targeted liver approach with strong fibrosis and lipid benefits

Retatrutide (LY3437943) is an investigational triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, with Phase 2 clinical data published in 2023 showing dose-dependent body weight reductions and HbA1c improvements

Management included immediate initiation of intravenous insulin with dextrose, which was continued in the neuro-intensive care unit (NICU) postoperatively for three days

The Centers for Medicare & Medicaid Services (CMS) has announced the launch of the Medicare GLP-1 Bridge, a new initiative designed to expand access to certain GLP-1 medications for eligible Medicare beneficiaries enrolled in Medicare Part D prescription drug coverage